Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer

Phase 2

Conditions: Lung Cancer, Non-small Cell
EGFR T790M
EGFR Gene Mutation

Interventions: Drug: Almonertinib
Drug: Pemetrexed
Drug: Carboplatin

First Posted Date: 2020-10-19

Last Posted Date: 2020-10-19

Lead Sponsor: Fudan University

Target Recruit Count: 226

Registration Number: NCT04592666

Locations: 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China

Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases

Phase 1

Active, not recruiting

Conditions: Brain Metastases
HER2-positive Breast Cancer
Breast Cancer

Interventions: Other: Pyrotinib Plus Capecitabine combined with brain radiotherapy

First Posted Date: 2020-10-12

Last Posted Date: 2023-01-18

Lead Sponsor: Fudan University

Target Recruit Count: 39

Registration Number: NCT04582968

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer

Phase 2

Conditions: Advanced Colorectal Carcinoma

Interventions: Drug: Fruquintinib and raltitrexed
Drug: Fruquintinib

First Posted Date: 2020-10-12

Last Posted Date: 2021-10-26

Lead Sponsor: Fudan University

Target Recruit Count: 136

Registration Number: NCT04582981

Locations: 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China

The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer

Phase 2

Conditions: Pancreatic Cancer
Chemotherapy Effect

Interventions: Drug: raltitrexed for injection
Drug: nab-paclitaxel

First Posted Date: 2020-10-09

Last Posted Date: 2020-10-09

Lead Sponsor: Fudan University

Target Recruit Count: 120

Registration Number: NCT04581876

Locations: 🇨🇳
Fudan University, Shanghai, Shanghai, China

Protective Effect of Intraoperative Parathyroid Gland Auxiliary Recognition System in Thyroid Malignant Tumor Operation

Not Applicable

Conditions: Intraoperative Monitoring
Thyroid Cancer
Parathyroid

Interventions: Device: Intraoperative parathyroid gland auxiliary recognition system

First Posted Date: 2020-09-23

Last Posted Date: 2020-09-23

Lead Sponsor: Fudan University

Target Recruit Count: 200

Registration Number: NCT04560426

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

The Value of ctDNA on Chemotherapy Efficacy for mCRC

Not Applicable

Recruiting

Conditions: Circulating Tumor DNA

Interventions: Genetic: ct-DNA

First Posted Date: 2020-09-18

Last Posted Date: 2021-07-19

Lead Sponsor: Fudan University

Target Recruit Count: 300

Registration Number: NCT04555369

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Eribulin in mTNBC Patients

Completed

Conditions: Breast Cancer

First Posted Date: 2020-09-09

Last Posted Date: 2021-02-03

Lead Sponsor: Fudan University

Target Recruit Count: 208

Registration Number: NCT04541420

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)

First Posted Date: 2020-09-03

Last Posted Date: 2024-02-26

Lead Sponsor: Fudan University

Target Recruit Count: 90

Registration Number: NCT04537286

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer

Phase 2

Conditions: Colorectal Cancer

Interventions: Radiation: Stereotactic Ablative Radiotherapy (SABR)
Drug: Sintilimab

First Posted Date: 2020-09-01

Last Posted Date: 2021-05-11

Lead Sponsor: Fudan University

Target Recruit Count: 60

Registration Number: NCT04535024

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Methylene Blue and Postoperative Neurocognitive Disorders

Not Applicable

Completed

Conditions: Postoperative Delirium
Postoperative Cognitive Dysfunction

Interventions: Drug: Placebo
Drug: Methylene Blue

First Posted Date: 2020-08-27

Last Posted Date: 2024-02-13

Lead Sponsor: Fudan University

Target Recruit Count: 314

Registration Number: NCT04529265

Locations: 🇨🇳
Shanghai Cancer Center, Fudan University, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy